We are live on
!
Find out more
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC
Delisted
CTIC was delisted on the 23rd of June, 2023.
38 hedge funds and large institutions have $33.7M invested in CTI BioPharma Corp. (DE) Common Stock in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
200% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 4
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
5% less funds holding
Funds holding: 40 → 38 (-2)
14% less capital invested
Capital invested by funds: $39.2M → $33.7M (-$5.53M)
Holders
38
Holders Change
-2
Holders Change %
-5%
% of All Funds
0.84%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
7
Increased
12
Reduced
4
Closed
6
Calls
$32K
Puts
–
Net Calls
+$32K
Net Calls Change
-$157K
Top Buyers
| 1 |
O
OrbiMed
New York
|
+$5.18M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$3.89M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$3.07M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$726K |
| 5 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$334K |
Top Sellers
| 1 |
JP Morgan Chase
New York
|
-$176K |
| 2 |
Two Sigma Investments
New York
|
-$35.4K |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$25K |
| 4 |
Goldman Sachs
New York
|
-$21K |
| 5 |
Morgan Stanley
New York
|
-$13.9K |
